Close Menu

NEW YORK – Share prices for several diagnostic companies declined sharply on Thursday after Abbott Laboratories and the US Food and Drug Administration announced that the firm had received Emergency Use Authorization for a rapid, low-cost SARS-CoV-2 antigen test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.